source
- Aardvark to unblind rare disease trial after FDA places full clinical hold; Alumis issues verdict on Acelyrin assetAardvark's rare disease candidate is under a full clinical hold by the FDA, which has paused all dosing and data collection. The company says it intends to unblind the trial data despite the hold,…
- OncLive poll highlights top GI cancer abstracts and interest areas for ASCO 2026OncLive conducted a poll among its audience to gauge which gastrointestinal cancer abstracts are expected to generate the most interest at the upcoming ASCO Annual Meeting. The poll results identi…